Sep 22, 2023 5:25pm EDT Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
Sep 06, 2023 7:00am EDT Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
Aug 22, 2023 7:30am EDT Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
Aug 09, 2023 4:05pm EDT Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
Aug 02, 2023 7:00am EDT Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
Jul 26, 2023 8:00am EDT Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
May 11, 2023 7:30am EDT Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
May 10, 2023 4:05pm EDT Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
May 03, 2023 7:00am EDT Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
Apr 18, 2023 8:00am EDT Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID
